columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
stelfonta
qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - psi - za liječenje neupotrebljiva, bez udaljenih metastaza (koji na pozornici) potkožnog pretilih stanica tumora, koji se nalazi na razini ili distalno na lakat ili skočnog zgloba kuka, i neupotrebljiva, sobe метастатические uzeli stanice kože рангоута tumora kod pasa.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
dilcoran 80 80 mg/1 tableta tableta sa modifikovanim oslobađanjem
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - pentaeritritil tetranitrat - tableta sa modifikovanim oslobađanjem - 80 mg/1 tableta - 1 tableta sa modifikovanim oslobađanjem sadrži: 80 mg pentaeritritil tetranitrata
lunsumio
roche registration gmbh - mosunetuzumab - limfom, folikularni - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
dilcoran 80 80 mg/1 tableta tableta sa modifikovanim oslobađanjem
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - pentaeritritil tetranitrat - tableta sa modifikovanim oslobađanjem - 80 mg/1 tableta - 1 tableta sa modifikovanim oslobađanjem sadrži: 80 mg pentaeritritil tetranitrata
lunsumio 1mg koncentrat za rastvor za infuziju
"hoffmann-la roche ltd" d.s.d. podgorica - mosunetuzumab - koncentrat za rastvor za infuziju - 1mg
lunsumio 30mg koncentrat za rastvor za infuziju
"hoffmann-la roche ltd" d.s.d. podgorica - mosunetuzumab - koncentrat za rastvor za infuziju - 30mg